ZC3HC1 Knockout cell line (MIA PaCa-2) – Genotype Verified & Ready-to-use

Red cotton OmniCell bank

10000⁺

Gene Knockout Cell Lines

2000⁺

Luc/EGFP/Cas9 Tool Cell Lines

1000⁺

Wild-type Cell Lines

ZC3HC1 Knockout cell line (MIA PaCa-2)

Copy Product Info

Catalog#

YKO-HA84265

Species

Human

Target Cell Line

MIA PaCa-2

Size

1*10^6

Gene

ZC3HC1

Storage conditions

Shipped on dry ice; Store in liquid nitrogen

Overview

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZC3HC1 (zinc finger C3HC-type containing 1) encodes an F-box-containing protein that functions as a component of an SCF-type E3 ubiquitin ligase complex. The complex regulates cell-cycle progression by targeting cyclin B1 for ubiquitin-mediated degradation, thereby controlling the transition from G2 phase to mitosis. ZC3HC1 therefore contributes to regulation of cell-cycle timing through targeted protein degradation.

A human pancreatic cancer model, MIA PaCa-2 originated from a primary pancreatic carcinoma of a 65-year-old male. The cells are classified as a human pancreatic cancer cell line and exhibit epithelial characteristics. MIA PaCa-2 has been extensively characterized by genomic and transcriptomic profiling and is represented in major cancer cell line resources.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

KO Cell Construction Strategy

Adopting Red Cotton CRISPR Gene Editing Designer (www.rc-crispr.com), two sgRNAs targeting the ZC3HC1 gene are designed to generate a knockout strategy. The two sgRNA sequences are subsequently cloned into the EZ-editor™ vector and introduced into MIA PaCa-2 cells via electroporation or lentiviral transduction. Single-cell clones are then generated using the limiting dilution method. Genomic DNA from individual clones is subjected to nucleic acid lysis and PCR amplification using the EZ-editor™ Monoclone Genotype Validation Kit (Cat# YK-MV-1000). The edited loci are further verified by Sanger sequencing to confirm the genotype. After secondary validation and quality confirmation, ZC3HC1 Knockout cell line (MIA PaCa-2) is expanded and cryopreserved for downstream applications.

Product Overview

ZC3HC1 Knockout cell line (MIA PaCa-2)

The ZC3HC1 Knockout cell line (MIA PaCa-2) is generated by targeted disruption of the ZC3HC1 gene in MIA PaCa-2 cells. This cell line is designed to investigate the role of ZC3HC1 in cellular function and gene regulation, as well as its potential involvement in disease-related pathways.

KO Cell Line

ZC3HC1 Knockout cell line (MIA PaCa-2)

Gene ID

51530

Catalog

YKO-HA84265

Gene Name

ZC3HC1

Product Category

Knockout(KO) Cell Line

Gene Information

NCBI

Species

Human

Mycoplasma test

Negative

Cell Morphology

Epithelial-like, adheren

Catalog Status

-

Culture method

87.5%DMEM+10%FBS+2.5%HS

Shipping

Cryopreserved Cells shipped in dry ice

Passage ratio

1：2-1：3

Storage Condition

Liquid nitrogen

Quality Control

All KO cell products are tested and confirmed to be free of bacterial, viral, mycoplasma contamination, and other adventitious agents.

Applications

For research use only. Not intended for use in diagnostic, therapeutic, clinical, or other applications.

Key Advantages

Easy to use

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations

High-efficient KO

These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.

Curated cells

Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Quality Control Specifications

1. Bacteria and Fungi Test

None Detected.

2. Mycoplasma test

Negative.

3. Knockout Strategy

Targeted knockout region: EExon 1

Reference Transcript: NM_001282191

Frameshift Mutation Strategy

4. STR Authentication

Download STR Report

Intended use

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use

Unpacking and Storage Instructions

1.

Cell Reception

2.

Unpacking and storage instructions

Handling procedure

1.

Cell Thawing

2.

Cell Passaging

3.

Cell cryopreservation

References

More

FAQ

Q1. How to Contact Support if Issues Arise After Receiving the KO Cells?

If any abnormalities are observed after receiving the cells, please provide the following information based on the stage of use and contact us promptly for assistance:

(1) Issues upon delivery: Please provide photos of the cells at the time of receipt along with a brief description of the issue. We will offer after-sales support accordingly.

(2) Issues after thawing or passaging: Please provide microscopic images of the cells before and after thawing/passaging, along with a detailed description of the experimental procedures. Our technical team will provide professional support.

Q2. What Information Is Required When Reporting KO Cell Product Issues?

Q3. How Should the KO cell Product Be Stored Upon Receipt?

Q4. Shipping Method

Q5. Are the Knockout Cell Lines Stable for Passaging? Is Authentication Provided?